Depressive symptoms and cognitive performance in older adults
Many longitudinal studies have found that older adults with depressive symptoms or depression have increased risk of cognitive impairment. We investigated the relationships between depressive symptoms or depression, cognitive function, serum brain-derived neurotrophic factor (BDNF), and volumetric M...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Shimada, Hiroyuki [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2014transfer abstract |
|---|
| Schlagwörter: |
|---|
| Umfang: |
8 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Trends in on-site removal, treatment, and sensitive assay of common pharmaceuticals in surface waters - Kaya, S. Irem ELSEVIER, 2022, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:57 ; year:2014 ; pages:149-156 ; extent:8 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.jpsychires.2014.06.004 |
|---|
| Katalog-ID: |
ELV028509374 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV028509374 | ||
| 003 | DE-627 | ||
| 005 | 20230625160621.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180603s2014 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jpsychires.2014.06.004 |2 doi | |
| 028 | 5 | 2 | |a GBVA2014022000008.pica |
| 035 | |a (DE-627)ELV028509374 | ||
| 035 | |a (ELSEVIER)S0022-3956(14)00172-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 540 |q VZ |
| 084 | |a 35.23 |2 bkl | ||
| 100 | 1 | |a Shimada, Hiroyuki |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Depressive symptoms and cognitive performance in older adults |
| 264 | 1 | |c 2014transfer abstract | |
| 300 | |a 8 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Many longitudinal studies have found that older adults with depressive symptoms or depression have increased risk of cognitive impairment. We investigated the relationships between depressive symptoms or depression, cognitive function, serum brain-derived neurotrophic factor (BDNF), and volumetric MRI measurements in older adults. A total of 4352 individuals aged 65 years or older (mean age 72 years) participated in the study. We investigated medical history and geriatric depression scale-15 (GDS-15) items to determine depression and depressive symptoms. Cognitive tests included the mini-mental state examination (MMSE), story memory, word list memory, trail-making tests, and the symbol digit substitution task. Of the 4352 participants, 570 (13%) fulfilled the criteria for depressive symptoms (GDS-15: 6 + points) and 87 (2%) were diagnosed with depression. All cognitive tests showed significant differences between the ‘no depressive symptoms’, ‘depressive symptoms’, and ‘depression’ groups. The ‘depressive symptoms’ and ‘depression’ groups showed lower serum BDNF (p < 0.001) concentrations than the ‘no depressive symptoms’ group. The ‘depressive symptoms’ group exhibited greater atrophy of the right medial temporal lobe than did the ‘no depressive symptoms’ group (p = 0.023). These results suggest that memory, executive function, and processing speed examinations are useful to identify cognitive decline in older adults who have depressive symptoms and depression. Serum BDNF concentration and atrophy of the right medial temporal lobe may in part mediate the relationships between depressive symptoms and cognitive decline. | ||
| 520 | |a Many longitudinal studies have found that older adults with depressive symptoms or depression have increased risk of cognitive impairment. We investigated the relationships between depressive symptoms or depression, cognitive function, serum brain-derived neurotrophic factor (BDNF), and volumetric MRI measurements in older adults. A total of 4352 individuals aged 65 years or older (mean age 72 years) participated in the study. We investigated medical history and geriatric depression scale-15 (GDS-15) items to determine depression and depressive symptoms. Cognitive tests included the mini-mental state examination (MMSE), story memory, word list memory, trail-making tests, and the symbol digit substitution task. Of the 4352 participants, 570 (13%) fulfilled the criteria for depressive symptoms (GDS-15: 6 + points) and 87 (2%) were diagnosed with depression. All cognitive tests showed significant differences between the ‘no depressive symptoms’, ‘depressive symptoms’, and ‘depression’ groups. The ‘depressive symptoms’ and ‘depression’ groups showed lower serum BDNF (p < 0.001) concentrations than the ‘no depressive symptoms’ group. The ‘depressive symptoms’ group exhibited greater atrophy of the right medial temporal lobe than did the ‘no depressive symptoms’ group (p = 0.023). These results suggest that memory, executive function, and processing speed examinations are useful to identify cognitive decline in older adults who have depressive symptoms and depression. Serum BDNF concentration and atrophy of the right medial temporal lobe may in part mediate the relationships between depressive symptoms and cognitive decline. | ||
| 650 | 7 | |a Cognitive test |2 Elsevier | |
| 650 | 7 | |a Geriatric depression scale |2 Elsevier | |
| 650 | 7 | |a BDNF |2 Elsevier | |
| 650 | 7 | |a Brain atrophy |2 Elsevier | |
| 650 | 7 | |a Elderly |2 Elsevier | |
| 650 | 7 | |a Hippocampus |2 Elsevier | |
| 700 | 1 | |a Park, Hyuntae |4 oth | |
| 700 | 1 | |a Makizako, Hyuma |4 oth | |
| 700 | 1 | |a Doi, Takehiko |4 oth | |
| 700 | 1 | |a Lee, Sangyoon |4 oth | |
| 700 | 1 | |a Suzuki, Takao |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Kaya, S. Irem ELSEVIER |t Trends in on-site removal, treatment, and sensitive assay of common pharmaceuticals in surface waters |d 2022 |g Amsterdam [u.a.] |w (DE-627)ELV007548370 |
| 773 | 1 | 8 | |g volume:57 |g year:2014 |g pages:149-156 |g extent:8 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.jpsychires.2014.06.004 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 35.23 |j Analytische Chemie: Allgemeines |q VZ |
| 951 | |a AR | ||
| 952 | |d 57 |j 2014 |h 149-156 |g 8 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
h s hs |
|---|---|
| matchkey_str |
shimadahiroyukiparkhyuntaemakizakohyumad:2014----:ersieyposncgiieefra |
| hierarchy_sort_str |
2014transfer abstract |
| bklnumber |
35.23 |
| publishDate |
2014 |
| allfields |
10.1016/j.jpsychires.2014.06.004 doi GBVA2014022000008.pica (DE-627)ELV028509374 (ELSEVIER)S0022-3956(14)00172-1 DE-627 ger DE-627 rakwb eng 610 610 DE-600 540 VZ 35.23 bkl Shimada, Hiroyuki verfasserin aut Depressive symptoms and cognitive performance in older adults 2014transfer abstract 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Many longitudinal studies have found that older adults with depressive symptoms or depression have increased risk of cognitive impairment. We investigated the relationships between depressive symptoms or depression, cognitive function, serum brain-derived neurotrophic factor (BDNF), and volumetric MRI measurements in older adults. A total of 4352 individuals aged 65 years or older (mean age 72 years) participated in the study. We investigated medical history and geriatric depression scale-15 (GDS-15) items to determine depression and depressive symptoms. Cognitive tests included the mini-mental state examination (MMSE), story memory, word list memory, trail-making tests, and the symbol digit substitution task. Of the 4352 participants, 570 (13%) fulfilled the criteria for depressive symptoms (GDS-15: 6 + points) and 87 (2%) were diagnosed with depression. All cognitive tests showed significant differences between the ‘no depressive symptoms’, ‘depressive symptoms’, and ‘depression’ groups. The ‘depressive symptoms’ and ‘depression’ groups showed lower serum BDNF (p < 0.001) concentrations than the ‘no depressive symptoms’ group. The ‘depressive symptoms’ group exhibited greater atrophy of the right medial temporal lobe than did the ‘no depressive symptoms’ group (p = 0.023). These results suggest that memory, executive function, and processing speed examinations are useful to identify cognitive decline in older adults who have depressive symptoms and depression. Serum BDNF concentration and atrophy of the right medial temporal lobe may in part mediate the relationships between depressive symptoms and cognitive decline. Many longitudinal studies have found that older adults with depressive symptoms or depression have increased risk of cognitive impairment. We investigated the relationships between depressive symptoms or depression, cognitive function, serum brain-derived neurotrophic factor (BDNF), and volumetric MRI measurements in older adults. A total of 4352 individuals aged 65 years or older (mean age 72 years) participated in the study. We investigated medical history and geriatric depression scale-15 (GDS-15) items to determine depression and depressive symptoms. Cognitive tests included the mini-mental state examination (MMSE), story memory, word list memory, trail-making tests, and the symbol digit substitution task. Of the 4352 participants, 570 (13%) fulfilled the criteria for depressive symptoms (GDS-15: 6 + points) and 87 (2%) were diagnosed with depression. All cognitive tests showed significant differences between the ‘no depressive symptoms’, ‘depressive symptoms’, and ‘depression’ groups. The ‘depressive symptoms’ and ‘depression’ groups showed lower serum BDNF (p < 0.001) concentrations than the ‘no depressive symptoms’ group. The ‘depressive symptoms’ group exhibited greater atrophy of the right medial temporal lobe than did the ‘no depressive symptoms’ group (p = 0.023). These results suggest that memory, executive function, and processing speed examinations are useful to identify cognitive decline in older adults who have depressive symptoms and depression. Serum BDNF concentration and atrophy of the right medial temporal lobe may in part mediate the relationships between depressive symptoms and cognitive decline. Cognitive test Elsevier Geriatric depression scale Elsevier BDNF Elsevier Brain atrophy Elsevier Elderly Elsevier Hippocampus Elsevier Park, Hyuntae oth Makizako, Hyuma oth Doi, Takehiko oth Lee, Sangyoon oth Suzuki, Takao oth Enthalten in Elsevier Science Kaya, S. Irem ELSEVIER Trends in on-site removal, treatment, and sensitive assay of common pharmaceuticals in surface waters 2022 Amsterdam [u.a.] (DE-627)ELV007548370 volume:57 year:2014 pages:149-156 extent:8 https://doi.org/10.1016/j.jpsychires.2014.06.004 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 35.23 Analytische Chemie: Allgemeines VZ AR 57 2014 149-156 8 045F 610 |
| spelling |
10.1016/j.jpsychires.2014.06.004 doi GBVA2014022000008.pica (DE-627)ELV028509374 (ELSEVIER)S0022-3956(14)00172-1 DE-627 ger DE-627 rakwb eng 610 610 DE-600 540 VZ 35.23 bkl Shimada, Hiroyuki verfasserin aut Depressive symptoms and cognitive performance in older adults 2014transfer abstract 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Many longitudinal studies have found that older adults with depressive symptoms or depression have increased risk of cognitive impairment. We investigated the relationships between depressive symptoms or depression, cognitive function, serum brain-derived neurotrophic factor (BDNF), and volumetric MRI measurements in older adults. A total of 4352 individuals aged 65 years or older (mean age 72 years) participated in the study. We investigated medical history and geriatric depression scale-15 (GDS-15) items to determine depression and depressive symptoms. Cognitive tests included the mini-mental state examination (MMSE), story memory, word list memory, trail-making tests, and the symbol digit substitution task. Of the 4352 participants, 570 (13%) fulfilled the criteria for depressive symptoms (GDS-15: 6 + points) and 87 (2%) were diagnosed with depression. All cognitive tests showed significant differences between the ‘no depressive symptoms’, ‘depressive symptoms’, and ‘depression’ groups. The ‘depressive symptoms’ and ‘depression’ groups showed lower serum BDNF (p < 0.001) concentrations than the ‘no depressive symptoms’ group. The ‘depressive symptoms’ group exhibited greater atrophy of the right medial temporal lobe than did the ‘no depressive symptoms’ group (p = 0.023). These results suggest that memory, executive function, and processing speed examinations are useful to identify cognitive decline in older adults who have depressive symptoms and depression. Serum BDNF concentration and atrophy of the right medial temporal lobe may in part mediate the relationships between depressive symptoms and cognitive decline. Many longitudinal studies have found that older adults with depressive symptoms or depression have increased risk of cognitive impairment. We investigated the relationships between depressive symptoms or depression, cognitive function, serum brain-derived neurotrophic factor (BDNF), and volumetric MRI measurements in older adults. A total of 4352 individuals aged 65 years or older (mean age 72 years) participated in the study. We investigated medical history and geriatric depression scale-15 (GDS-15) items to determine depression and depressive symptoms. Cognitive tests included the mini-mental state examination (MMSE), story memory, word list memory, trail-making tests, and the symbol digit substitution task. Of the 4352 participants, 570 (13%) fulfilled the criteria for depressive symptoms (GDS-15: 6 + points) and 87 (2%) were diagnosed with depression. All cognitive tests showed significant differences between the ‘no depressive symptoms’, ‘depressive symptoms’, and ‘depression’ groups. The ‘depressive symptoms’ and ‘depression’ groups showed lower serum BDNF (p < 0.001) concentrations than the ‘no depressive symptoms’ group. The ‘depressive symptoms’ group exhibited greater atrophy of the right medial temporal lobe than did the ‘no depressive symptoms’ group (p = 0.023). These results suggest that memory, executive function, and processing speed examinations are useful to identify cognitive decline in older adults who have depressive symptoms and depression. Serum BDNF concentration and atrophy of the right medial temporal lobe may in part mediate the relationships between depressive symptoms and cognitive decline. Cognitive test Elsevier Geriatric depression scale Elsevier BDNF Elsevier Brain atrophy Elsevier Elderly Elsevier Hippocampus Elsevier Park, Hyuntae oth Makizako, Hyuma oth Doi, Takehiko oth Lee, Sangyoon oth Suzuki, Takao oth Enthalten in Elsevier Science Kaya, S. Irem ELSEVIER Trends in on-site removal, treatment, and sensitive assay of common pharmaceuticals in surface waters 2022 Amsterdam [u.a.] (DE-627)ELV007548370 volume:57 year:2014 pages:149-156 extent:8 https://doi.org/10.1016/j.jpsychires.2014.06.004 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 35.23 Analytische Chemie: Allgemeines VZ AR 57 2014 149-156 8 045F 610 |
| allfields_unstemmed |
10.1016/j.jpsychires.2014.06.004 doi GBVA2014022000008.pica (DE-627)ELV028509374 (ELSEVIER)S0022-3956(14)00172-1 DE-627 ger DE-627 rakwb eng 610 610 DE-600 540 VZ 35.23 bkl Shimada, Hiroyuki verfasserin aut Depressive symptoms and cognitive performance in older adults 2014transfer abstract 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Many longitudinal studies have found that older adults with depressive symptoms or depression have increased risk of cognitive impairment. We investigated the relationships between depressive symptoms or depression, cognitive function, serum brain-derived neurotrophic factor (BDNF), and volumetric MRI measurements in older adults. A total of 4352 individuals aged 65 years or older (mean age 72 years) participated in the study. We investigated medical history and geriatric depression scale-15 (GDS-15) items to determine depression and depressive symptoms. Cognitive tests included the mini-mental state examination (MMSE), story memory, word list memory, trail-making tests, and the symbol digit substitution task. Of the 4352 participants, 570 (13%) fulfilled the criteria for depressive symptoms (GDS-15: 6 + points) and 87 (2%) were diagnosed with depression. All cognitive tests showed significant differences between the ‘no depressive symptoms’, ‘depressive symptoms’, and ‘depression’ groups. The ‘depressive symptoms’ and ‘depression’ groups showed lower serum BDNF (p < 0.001) concentrations than the ‘no depressive symptoms’ group. The ‘depressive symptoms’ group exhibited greater atrophy of the right medial temporal lobe than did the ‘no depressive symptoms’ group (p = 0.023). These results suggest that memory, executive function, and processing speed examinations are useful to identify cognitive decline in older adults who have depressive symptoms and depression. Serum BDNF concentration and atrophy of the right medial temporal lobe may in part mediate the relationships between depressive symptoms and cognitive decline. Many longitudinal studies have found that older adults with depressive symptoms or depression have increased risk of cognitive impairment. We investigated the relationships between depressive symptoms or depression, cognitive function, serum brain-derived neurotrophic factor (BDNF), and volumetric MRI measurements in older adults. A total of 4352 individuals aged 65 years or older (mean age 72 years) participated in the study. We investigated medical history and geriatric depression scale-15 (GDS-15) items to determine depression and depressive symptoms. Cognitive tests included the mini-mental state examination (MMSE), story memory, word list memory, trail-making tests, and the symbol digit substitution task. Of the 4352 participants, 570 (13%) fulfilled the criteria for depressive symptoms (GDS-15: 6 + points) and 87 (2%) were diagnosed with depression. All cognitive tests showed significant differences between the ‘no depressive symptoms’, ‘depressive symptoms’, and ‘depression’ groups. The ‘depressive symptoms’ and ‘depression’ groups showed lower serum BDNF (p < 0.001) concentrations than the ‘no depressive symptoms’ group. The ‘depressive symptoms’ group exhibited greater atrophy of the right medial temporal lobe than did the ‘no depressive symptoms’ group (p = 0.023). These results suggest that memory, executive function, and processing speed examinations are useful to identify cognitive decline in older adults who have depressive symptoms and depression. Serum BDNF concentration and atrophy of the right medial temporal lobe may in part mediate the relationships between depressive symptoms and cognitive decline. Cognitive test Elsevier Geriatric depression scale Elsevier BDNF Elsevier Brain atrophy Elsevier Elderly Elsevier Hippocampus Elsevier Park, Hyuntae oth Makizako, Hyuma oth Doi, Takehiko oth Lee, Sangyoon oth Suzuki, Takao oth Enthalten in Elsevier Science Kaya, S. Irem ELSEVIER Trends in on-site removal, treatment, and sensitive assay of common pharmaceuticals in surface waters 2022 Amsterdam [u.a.] (DE-627)ELV007548370 volume:57 year:2014 pages:149-156 extent:8 https://doi.org/10.1016/j.jpsychires.2014.06.004 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 35.23 Analytische Chemie: Allgemeines VZ AR 57 2014 149-156 8 045F 610 |
| allfieldsGer |
10.1016/j.jpsychires.2014.06.004 doi GBVA2014022000008.pica (DE-627)ELV028509374 (ELSEVIER)S0022-3956(14)00172-1 DE-627 ger DE-627 rakwb eng 610 610 DE-600 540 VZ 35.23 bkl Shimada, Hiroyuki verfasserin aut Depressive symptoms and cognitive performance in older adults 2014transfer abstract 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Many longitudinal studies have found that older adults with depressive symptoms or depression have increased risk of cognitive impairment. We investigated the relationships between depressive symptoms or depression, cognitive function, serum brain-derived neurotrophic factor (BDNF), and volumetric MRI measurements in older adults. A total of 4352 individuals aged 65 years or older (mean age 72 years) participated in the study. We investigated medical history and geriatric depression scale-15 (GDS-15) items to determine depression and depressive symptoms. Cognitive tests included the mini-mental state examination (MMSE), story memory, word list memory, trail-making tests, and the symbol digit substitution task. Of the 4352 participants, 570 (13%) fulfilled the criteria for depressive symptoms (GDS-15: 6 + points) and 87 (2%) were diagnosed with depression. All cognitive tests showed significant differences between the ‘no depressive symptoms’, ‘depressive symptoms’, and ‘depression’ groups. The ‘depressive symptoms’ and ‘depression’ groups showed lower serum BDNF (p < 0.001) concentrations than the ‘no depressive symptoms’ group. The ‘depressive symptoms’ group exhibited greater atrophy of the right medial temporal lobe than did the ‘no depressive symptoms’ group (p = 0.023). These results suggest that memory, executive function, and processing speed examinations are useful to identify cognitive decline in older adults who have depressive symptoms and depression. Serum BDNF concentration and atrophy of the right medial temporal lobe may in part mediate the relationships between depressive symptoms and cognitive decline. Many longitudinal studies have found that older adults with depressive symptoms or depression have increased risk of cognitive impairment. We investigated the relationships between depressive symptoms or depression, cognitive function, serum brain-derived neurotrophic factor (BDNF), and volumetric MRI measurements in older adults. A total of 4352 individuals aged 65 years or older (mean age 72 years) participated in the study. We investigated medical history and geriatric depression scale-15 (GDS-15) items to determine depression and depressive symptoms. Cognitive tests included the mini-mental state examination (MMSE), story memory, word list memory, trail-making tests, and the symbol digit substitution task. Of the 4352 participants, 570 (13%) fulfilled the criteria for depressive symptoms (GDS-15: 6 + points) and 87 (2%) were diagnosed with depression. All cognitive tests showed significant differences between the ‘no depressive symptoms’, ‘depressive symptoms’, and ‘depression’ groups. The ‘depressive symptoms’ and ‘depression’ groups showed lower serum BDNF (p < 0.001) concentrations than the ‘no depressive symptoms’ group. The ‘depressive symptoms’ group exhibited greater atrophy of the right medial temporal lobe than did the ‘no depressive symptoms’ group (p = 0.023). These results suggest that memory, executive function, and processing speed examinations are useful to identify cognitive decline in older adults who have depressive symptoms and depression. Serum BDNF concentration and atrophy of the right medial temporal lobe may in part mediate the relationships between depressive symptoms and cognitive decline. Cognitive test Elsevier Geriatric depression scale Elsevier BDNF Elsevier Brain atrophy Elsevier Elderly Elsevier Hippocampus Elsevier Park, Hyuntae oth Makizako, Hyuma oth Doi, Takehiko oth Lee, Sangyoon oth Suzuki, Takao oth Enthalten in Elsevier Science Kaya, S. Irem ELSEVIER Trends in on-site removal, treatment, and sensitive assay of common pharmaceuticals in surface waters 2022 Amsterdam [u.a.] (DE-627)ELV007548370 volume:57 year:2014 pages:149-156 extent:8 https://doi.org/10.1016/j.jpsychires.2014.06.004 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 35.23 Analytische Chemie: Allgemeines VZ AR 57 2014 149-156 8 045F 610 |
| allfieldsSound |
10.1016/j.jpsychires.2014.06.004 doi GBVA2014022000008.pica (DE-627)ELV028509374 (ELSEVIER)S0022-3956(14)00172-1 DE-627 ger DE-627 rakwb eng 610 610 DE-600 540 VZ 35.23 bkl Shimada, Hiroyuki verfasserin aut Depressive symptoms and cognitive performance in older adults 2014transfer abstract 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Many longitudinal studies have found that older adults with depressive symptoms or depression have increased risk of cognitive impairment. We investigated the relationships between depressive symptoms or depression, cognitive function, serum brain-derived neurotrophic factor (BDNF), and volumetric MRI measurements in older adults. A total of 4352 individuals aged 65 years or older (mean age 72 years) participated in the study. We investigated medical history and geriatric depression scale-15 (GDS-15) items to determine depression and depressive symptoms. Cognitive tests included the mini-mental state examination (MMSE), story memory, word list memory, trail-making tests, and the symbol digit substitution task. Of the 4352 participants, 570 (13%) fulfilled the criteria for depressive symptoms (GDS-15: 6 + points) and 87 (2%) were diagnosed with depression. All cognitive tests showed significant differences between the ‘no depressive symptoms’, ‘depressive symptoms’, and ‘depression’ groups. The ‘depressive symptoms’ and ‘depression’ groups showed lower serum BDNF (p < 0.001) concentrations than the ‘no depressive symptoms’ group. The ‘depressive symptoms’ group exhibited greater atrophy of the right medial temporal lobe than did the ‘no depressive symptoms’ group (p = 0.023). These results suggest that memory, executive function, and processing speed examinations are useful to identify cognitive decline in older adults who have depressive symptoms and depression. Serum BDNF concentration and atrophy of the right medial temporal lobe may in part mediate the relationships between depressive symptoms and cognitive decline. Many longitudinal studies have found that older adults with depressive symptoms or depression have increased risk of cognitive impairment. We investigated the relationships between depressive symptoms or depression, cognitive function, serum brain-derived neurotrophic factor (BDNF), and volumetric MRI measurements in older adults. A total of 4352 individuals aged 65 years or older (mean age 72 years) participated in the study. We investigated medical history and geriatric depression scale-15 (GDS-15) items to determine depression and depressive symptoms. Cognitive tests included the mini-mental state examination (MMSE), story memory, word list memory, trail-making tests, and the symbol digit substitution task. Of the 4352 participants, 570 (13%) fulfilled the criteria for depressive symptoms (GDS-15: 6 + points) and 87 (2%) were diagnosed with depression. All cognitive tests showed significant differences between the ‘no depressive symptoms’, ‘depressive symptoms’, and ‘depression’ groups. The ‘depressive symptoms’ and ‘depression’ groups showed lower serum BDNF (p < 0.001) concentrations than the ‘no depressive symptoms’ group. The ‘depressive symptoms’ group exhibited greater atrophy of the right medial temporal lobe than did the ‘no depressive symptoms’ group (p = 0.023). These results suggest that memory, executive function, and processing speed examinations are useful to identify cognitive decline in older adults who have depressive symptoms and depression. Serum BDNF concentration and atrophy of the right medial temporal lobe may in part mediate the relationships between depressive symptoms and cognitive decline. Cognitive test Elsevier Geriatric depression scale Elsevier BDNF Elsevier Brain atrophy Elsevier Elderly Elsevier Hippocampus Elsevier Park, Hyuntae oth Makizako, Hyuma oth Doi, Takehiko oth Lee, Sangyoon oth Suzuki, Takao oth Enthalten in Elsevier Science Kaya, S. Irem ELSEVIER Trends in on-site removal, treatment, and sensitive assay of common pharmaceuticals in surface waters 2022 Amsterdam [u.a.] (DE-627)ELV007548370 volume:57 year:2014 pages:149-156 extent:8 https://doi.org/10.1016/j.jpsychires.2014.06.004 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 35.23 Analytische Chemie: Allgemeines VZ AR 57 2014 149-156 8 045F 610 |
| language |
English |
| source |
Enthalten in Trends in on-site removal, treatment, and sensitive assay of common pharmaceuticals in surface waters Amsterdam [u.a.] volume:57 year:2014 pages:149-156 extent:8 |
| sourceStr |
Enthalten in Trends in on-site removal, treatment, and sensitive assay of common pharmaceuticals in surface waters Amsterdam [u.a.] volume:57 year:2014 pages:149-156 extent:8 |
| format_phy_str_mv |
Article |
| bklname |
Analytische Chemie: Allgemeines |
| institution |
findex.gbv.de |
| topic_facet |
Cognitive test Geriatric depression scale BDNF Brain atrophy Elderly Hippocampus |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Trends in on-site removal, treatment, and sensitive assay of common pharmaceuticals in surface waters |
| authorswithroles_txt_mv |
Shimada, Hiroyuki @@aut@@ Park, Hyuntae @@oth@@ Makizako, Hyuma @@oth@@ Doi, Takehiko @@oth@@ Lee, Sangyoon @@oth@@ Suzuki, Takao @@oth@@ |
| publishDateDaySort_date |
2014-01-01T00:00:00Z |
| hierarchy_top_id |
ELV007548370 |
| dewey-sort |
3610 |
| id |
ELV028509374 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV028509374</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625160621.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2014 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.jpsychires.2014.06.004</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2014022000008.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV028509374</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0022-3956(14)00172-1</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">35.23</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Shimada, Hiroyuki</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Depressive symptoms and cognitive performance in older adults</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2014transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">8</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Many longitudinal studies have found that older adults with depressive symptoms or depression have increased risk of cognitive impairment. We investigated the relationships between depressive symptoms or depression, cognitive function, serum brain-derived neurotrophic factor (BDNF), and volumetric MRI measurements in older adults. A total of 4352 individuals aged 65 years or older (mean age 72 years) participated in the study. We investigated medical history and geriatric depression scale-15 (GDS-15) items to determine depression and depressive symptoms. Cognitive tests included the mini-mental state examination (MMSE), story memory, word list memory, trail-making tests, and the symbol digit substitution task. Of the 4352 participants, 570 (13%) fulfilled the criteria for depressive symptoms (GDS-15: 6 + points) and 87 (2%) were diagnosed with depression. All cognitive tests showed significant differences between the ‘no depressive symptoms’, ‘depressive symptoms’, and ‘depression’ groups. The ‘depressive symptoms’ and ‘depression’ groups showed lower serum BDNF (p < 0.001) concentrations than the ‘no depressive symptoms’ group. The ‘depressive symptoms’ group exhibited greater atrophy of the right medial temporal lobe than did the ‘no depressive symptoms’ group (p = 0.023). These results suggest that memory, executive function, and processing speed examinations are useful to identify cognitive decline in older adults who have depressive symptoms and depression. Serum BDNF concentration and atrophy of the right medial temporal lobe may in part mediate the relationships between depressive symptoms and cognitive decline.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Many longitudinal studies have found that older adults with depressive symptoms or depression have increased risk of cognitive impairment. We investigated the relationships between depressive symptoms or depression, cognitive function, serum brain-derived neurotrophic factor (BDNF), and volumetric MRI measurements in older adults. A total of 4352 individuals aged 65 years or older (mean age 72 years) participated in the study. We investigated medical history and geriatric depression scale-15 (GDS-15) items to determine depression and depressive symptoms. Cognitive tests included the mini-mental state examination (MMSE), story memory, word list memory, trail-making tests, and the symbol digit substitution task. Of the 4352 participants, 570 (13%) fulfilled the criteria for depressive symptoms (GDS-15: 6 + points) and 87 (2%) were diagnosed with depression. All cognitive tests showed significant differences between the ‘no depressive symptoms’, ‘depressive symptoms’, and ‘depression’ groups. The ‘depressive symptoms’ and ‘depression’ groups showed lower serum BDNF (p < 0.001) concentrations than the ‘no depressive symptoms’ group. The ‘depressive symptoms’ group exhibited greater atrophy of the right medial temporal lobe than did the ‘no depressive symptoms’ group (p = 0.023). These results suggest that memory, executive function, and processing speed examinations are useful to identify cognitive decline in older adults who have depressive symptoms and depression. Serum BDNF concentration and atrophy of the right medial temporal lobe may in part mediate the relationships between depressive symptoms and cognitive decline.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Cognitive test</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Geriatric depression scale</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">BDNF</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Brain atrophy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Elderly</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Hippocampus</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Park, Hyuntae</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Makizako, Hyuma</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Doi, Takehiko</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lee, Sangyoon</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Suzuki, Takao</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Kaya, S. Irem ELSEVIER</subfield><subfield code="t">Trends in on-site removal, treatment, and sensitive assay of common pharmaceuticals in surface waters</subfield><subfield code="d">2022</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV007548370</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:57</subfield><subfield code="g">year:2014</subfield><subfield code="g">pages:149-156</subfield><subfield code="g">extent:8</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.jpsychires.2014.06.004</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">35.23</subfield><subfield code="j">Analytische Chemie: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">57</subfield><subfield code="j">2014</subfield><subfield code="h">149-156</subfield><subfield code="g">8</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Shimada, Hiroyuki |
| spellingShingle |
Shimada, Hiroyuki ddc 610 ddc 540 bkl 35.23 Elsevier Cognitive test Elsevier Geriatric depression scale Elsevier BDNF Elsevier Brain atrophy Elsevier Elderly Elsevier Hippocampus Depressive symptoms and cognitive performance in older adults |
| authorStr |
Shimada, Hiroyuki |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV007548370 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health 540 - Chemistry & allied sciences |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 540 VZ 35.23 bkl Depressive symptoms and cognitive performance in older adults Cognitive test Elsevier Geriatric depression scale Elsevier BDNF Elsevier Brain atrophy Elsevier Elderly Elsevier Hippocampus Elsevier |
| topic |
ddc 610 ddc 540 bkl 35.23 Elsevier Cognitive test Elsevier Geriatric depression scale Elsevier BDNF Elsevier Brain atrophy Elsevier Elderly Elsevier Hippocampus |
| topic_unstemmed |
ddc 610 ddc 540 bkl 35.23 Elsevier Cognitive test Elsevier Geriatric depression scale Elsevier BDNF Elsevier Brain atrophy Elsevier Elderly Elsevier Hippocampus |
| topic_browse |
ddc 610 ddc 540 bkl 35.23 Elsevier Cognitive test Elsevier Geriatric depression scale Elsevier BDNF Elsevier Brain atrophy Elsevier Elderly Elsevier Hippocampus |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
h p hp h m hm t d td s l sl t s ts |
| hierarchy_parent_title |
Trends in on-site removal, treatment, and sensitive assay of common pharmaceuticals in surface waters |
| hierarchy_parent_id |
ELV007548370 |
| dewey-tens |
610 - Medicine & health 540 - Chemistry |
| hierarchy_top_title |
Trends in on-site removal, treatment, and sensitive assay of common pharmaceuticals in surface waters |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV007548370 |
| title |
Depressive symptoms and cognitive performance in older adults |
| ctrlnum |
(DE-627)ELV028509374 (ELSEVIER)S0022-3956(14)00172-1 |
| title_full |
Depressive symptoms and cognitive performance in older adults |
| author_sort |
Shimada, Hiroyuki |
| journal |
Trends in on-site removal, treatment, and sensitive assay of common pharmaceuticals in surface waters |
| journalStr |
Trends in on-site removal, treatment, and sensitive assay of common pharmaceuticals in surface waters |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology 500 - Science |
| recordtype |
marc |
| publishDateSort |
2014 |
| contenttype_str_mv |
zzz |
| container_start_page |
149 |
| author_browse |
Shimada, Hiroyuki |
| container_volume |
57 |
| physical |
8 |
| class |
610 610 DE-600 540 VZ 35.23 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Shimada, Hiroyuki |
| doi_str_mv |
10.1016/j.jpsychires.2014.06.004 |
| dewey-full |
610 540 |
| title_sort |
depressive symptoms and cognitive performance in older adults |
| title_auth |
Depressive symptoms and cognitive performance in older adults |
| abstract |
Many longitudinal studies have found that older adults with depressive symptoms or depression have increased risk of cognitive impairment. We investigated the relationships between depressive symptoms or depression, cognitive function, serum brain-derived neurotrophic factor (BDNF), and volumetric MRI measurements in older adults. A total of 4352 individuals aged 65 years or older (mean age 72 years) participated in the study. We investigated medical history and geriatric depression scale-15 (GDS-15) items to determine depression and depressive symptoms. Cognitive tests included the mini-mental state examination (MMSE), story memory, word list memory, trail-making tests, and the symbol digit substitution task. Of the 4352 participants, 570 (13%) fulfilled the criteria for depressive symptoms (GDS-15: 6 + points) and 87 (2%) were diagnosed with depression. All cognitive tests showed significant differences between the ‘no depressive symptoms’, ‘depressive symptoms’, and ‘depression’ groups. The ‘depressive symptoms’ and ‘depression’ groups showed lower serum BDNF (p < 0.001) concentrations than the ‘no depressive symptoms’ group. The ‘depressive symptoms’ group exhibited greater atrophy of the right medial temporal lobe than did the ‘no depressive symptoms’ group (p = 0.023). These results suggest that memory, executive function, and processing speed examinations are useful to identify cognitive decline in older adults who have depressive symptoms and depression. Serum BDNF concentration and atrophy of the right medial temporal lobe may in part mediate the relationships between depressive symptoms and cognitive decline. |
| abstractGer |
Many longitudinal studies have found that older adults with depressive symptoms or depression have increased risk of cognitive impairment. We investigated the relationships between depressive symptoms or depression, cognitive function, serum brain-derived neurotrophic factor (BDNF), and volumetric MRI measurements in older adults. A total of 4352 individuals aged 65 years or older (mean age 72 years) participated in the study. We investigated medical history and geriatric depression scale-15 (GDS-15) items to determine depression and depressive symptoms. Cognitive tests included the mini-mental state examination (MMSE), story memory, word list memory, trail-making tests, and the symbol digit substitution task. Of the 4352 participants, 570 (13%) fulfilled the criteria for depressive symptoms (GDS-15: 6 + points) and 87 (2%) were diagnosed with depression. All cognitive tests showed significant differences between the ‘no depressive symptoms’, ‘depressive symptoms’, and ‘depression’ groups. The ‘depressive symptoms’ and ‘depression’ groups showed lower serum BDNF (p < 0.001) concentrations than the ‘no depressive symptoms’ group. The ‘depressive symptoms’ group exhibited greater atrophy of the right medial temporal lobe than did the ‘no depressive symptoms’ group (p = 0.023). These results suggest that memory, executive function, and processing speed examinations are useful to identify cognitive decline in older adults who have depressive symptoms and depression. Serum BDNF concentration and atrophy of the right medial temporal lobe may in part mediate the relationships between depressive symptoms and cognitive decline. |
| abstract_unstemmed |
Many longitudinal studies have found that older adults with depressive symptoms or depression have increased risk of cognitive impairment. We investigated the relationships between depressive symptoms or depression, cognitive function, serum brain-derived neurotrophic factor (BDNF), and volumetric MRI measurements in older adults. A total of 4352 individuals aged 65 years or older (mean age 72 years) participated in the study. We investigated medical history and geriatric depression scale-15 (GDS-15) items to determine depression and depressive symptoms. Cognitive tests included the mini-mental state examination (MMSE), story memory, word list memory, trail-making tests, and the symbol digit substitution task. Of the 4352 participants, 570 (13%) fulfilled the criteria for depressive symptoms (GDS-15: 6 + points) and 87 (2%) were diagnosed with depression. All cognitive tests showed significant differences between the ‘no depressive symptoms’, ‘depressive symptoms’, and ‘depression’ groups. The ‘depressive symptoms’ and ‘depression’ groups showed lower serum BDNF (p < 0.001) concentrations than the ‘no depressive symptoms’ group. The ‘depressive symptoms’ group exhibited greater atrophy of the right medial temporal lobe than did the ‘no depressive symptoms’ group (p = 0.023). These results suggest that memory, executive function, and processing speed examinations are useful to identify cognitive decline in older adults who have depressive symptoms and depression. Serum BDNF concentration and atrophy of the right medial temporal lobe may in part mediate the relationships between depressive symptoms and cognitive decline. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA |
| title_short |
Depressive symptoms and cognitive performance in older adults |
| url |
https://doi.org/10.1016/j.jpsychires.2014.06.004 |
| remote_bool |
true |
| author2 |
Park, Hyuntae Makizako, Hyuma Doi, Takehiko Lee, Sangyoon Suzuki, Takao |
| author2Str |
Park, Hyuntae Makizako, Hyuma Doi, Takehiko Lee, Sangyoon Suzuki, Takao |
| ppnlink |
ELV007548370 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth |
| doi_str |
10.1016/j.jpsychires.2014.06.004 |
| up_date |
2024-07-06T19:00:13.535Z |
| _version_ |
1803857337816973312 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV028509374</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625160621.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2014 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.jpsychires.2014.06.004</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2014022000008.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV028509374</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0022-3956(14)00172-1</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">35.23</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Shimada, Hiroyuki</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Depressive symptoms and cognitive performance in older adults</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2014transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">8</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Many longitudinal studies have found that older adults with depressive symptoms or depression have increased risk of cognitive impairment. We investigated the relationships between depressive symptoms or depression, cognitive function, serum brain-derived neurotrophic factor (BDNF), and volumetric MRI measurements in older adults. A total of 4352 individuals aged 65 years or older (mean age 72 years) participated in the study. We investigated medical history and geriatric depression scale-15 (GDS-15) items to determine depression and depressive symptoms. Cognitive tests included the mini-mental state examination (MMSE), story memory, word list memory, trail-making tests, and the symbol digit substitution task. Of the 4352 participants, 570 (13%) fulfilled the criteria for depressive symptoms (GDS-15: 6 + points) and 87 (2%) were diagnosed with depression. All cognitive tests showed significant differences between the ‘no depressive symptoms’, ‘depressive symptoms’, and ‘depression’ groups. The ‘depressive symptoms’ and ‘depression’ groups showed lower serum BDNF (p < 0.001) concentrations than the ‘no depressive symptoms’ group. The ‘depressive symptoms’ group exhibited greater atrophy of the right medial temporal lobe than did the ‘no depressive symptoms’ group (p = 0.023). These results suggest that memory, executive function, and processing speed examinations are useful to identify cognitive decline in older adults who have depressive symptoms and depression. Serum BDNF concentration and atrophy of the right medial temporal lobe may in part mediate the relationships between depressive symptoms and cognitive decline.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Many longitudinal studies have found that older adults with depressive symptoms or depression have increased risk of cognitive impairment. We investigated the relationships between depressive symptoms or depression, cognitive function, serum brain-derived neurotrophic factor (BDNF), and volumetric MRI measurements in older adults. A total of 4352 individuals aged 65 years or older (mean age 72 years) participated in the study. We investigated medical history and geriatric depression scale-15 (GDS-15) items to determine depression and depressive symptoms. Cognitive tests included the mini-mental state examination (MMSE), story memory, word list memory, trail-making tests, and the symbol digit substitution task. Of the 4352 participants, 570 (13%) fulfilled the criteria for depressive symptoms (GDS-15: 6 + points) and 87 (2%) were diagnosed with depression. All cognitive tests showed significant differences between the ‘no depressive symptoms’, ‘depressive symptoms’, and ‘depression’ groups. The ‘depressive symptoms’ and ‘depression’ groups showed lower serum BDNF (p < 0.001) concentrations than the ‘no depressive symptoms’ group. The ‘depressive symptoms’ group exhibited greater atrophy of the right medial temporal lobe than did the ‘no depressive symptoms’ group (p = 0.023). These results suggest that memory, executive function, and processing speed examinations are useful to identify cognitive decline in older adults who have depressive symptoms and depression. Serum BDNF concentration and atrophy of the right medial temporal lobe may in part mediate the relationships between depressive symptoms and cognitive decline.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Cognitive test</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Geriatric depression scale</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">BDNF</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Brain atrophy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Elderly</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Hippocampus</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Park, Hyuntae</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Makizako, Hyuma</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Doi, Takehiko</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lee, Sangyoon</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Suzuki, Takao</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Kaya, S. Irem ELSEVIER</subfield><subfield code="t">Trends in on-site removal, treatment, and sensitive assay of common pharmaceuticals in surface waters</subfield><subfield code="d">2022</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV007548370</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:57</subfield><subfield code="g">year:2014</subfield><subfield code="g">pages:149-156</subfield><subfield code="g">extent:8</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.jpsychires.2014.06.004</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">35.23</subfield><subfield code="j">Analytische Chemie: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">57</subfield><subfield code="j">2014</subfield><subfield code="h">149-156</subfield><subfield code="g">8</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.4011145 |